Larazotide Acetate

Phase 3 Clinical Trials

peptideOral

Tightens seals between gut lining cells, directly addressing leaky gut. Developed for celiac disease but useful for gut barrier problems broadly.

Key Facts

Classification
Peptide — Seals leaky gut by tightening junctions between intestinal cells.
Primary Benefits
Gut Health (8/10) · Inflammation (6/10) · Immune Support (4/10)
Administration
Oral
Typical Dose
0.5-1 mg by mouth 3 times daily before meals. Cycle for 8-12 weeks.
Evidence Strength
Moderate — 20 peer-reviewed studies referenced · Community sentiment 10/10
Stacks Well With
BPC-157, KPV
Legal Status
Phase 3 Clinical Trials · not prescribable in US

Tightening of intestinal tight junctions beginning. Reduced gut permeability. Subtle improvement in food-sensitivity reactions.

Significant reduction in leaky gut symptoms. Improved tolerance of gluten (in celiac patients). Reduced bloating and GI discomfort.

Sustained intestinal barrier restoration. Reduced systemic inflammation from gut permeability. Improved nutrient absorption.

Mild GI discomfortHeadacheNausea (uncommon)Generally well-tolerated in trials

Tolerance: None observed in clinical trials

Cycling: 8-12 weeks on, 4 weeks off. In clinical trials for celiac disease — follow prescriber guidance.

0.5-1 mg by mouth 3 times daily before meals. Cycle for 8-12 weeks.

Reconstitution, storage, injection sites & timing

🫃 Gut Health

8/10

🧊 Inflammation

6/10

🛡️ Immune Support

4/10

Medical oversight recommendedNot safe during pregnancy· 2 contraindications